Condition: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency · Autosomal Recessive Hypophosphatemic Rickets · Generalized Arterial Calcification of Infancy · Sponsor: Inozyme Pharma
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for the treatment of ENPP1 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ENPP1 Deficiency.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Clinilabs Drug Development Corporation | Eatontown, New Jersey, United States | — |
| University of Saskatchewan | Saskatoon, Saskatchewan, Canada | — |
| Necker University Hospital-Sick Children | Paris, France | — |
| Parexel International GmbH | Berlin, Germany | — |
| University of Hamburg (Universitatklinikum Hamburg-Eppendorf) | Hamburg, Germany | — |
| Richmond Pharmacology (RPL) | London, London Bridge, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04686175